Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foxy-5 neoadjuvant phase II trial in colon cancer
NL-OMON45868Phase 2Withdrawn
- Sponsor
- WntResearch AB
- Start
- Oct 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Foxy-5 in colon cancer (2 arms), sponsored by WntResearch AB. Primary endpoints: Incidence of grade 3 or higher adverse events related to Foxy-5 and ctDNA level in plasma in Wnt-5a low colon cancer. Planned start Oct 2018; status: withdrawn.
02
Drugs
Foxy-5
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON45868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45868.